³í´Ü

¹ÚÁÖÈ«
COVID19¿¡ ´ëÇÑ Àå³» ¸¶ÀÌÅ©·Î¹ÙÀÌ¿ÈÀÇ ¿ªÇÒ°ú È°¿ë
±èµ¿Çö ¼­¿ï´ëÇб³ ÀÇ°ú´ëÇÐ ÀÇ°úÇаú/¹Ì»ý¹°Çб³½Ç
¸ÞÀÏ biologokim@snu.ac.kr

[º»¹®]

Introduction

   Äڷγª¹ÙÀÌ·¯½º Áúº´ 2019 (Coronavirus Disease 2019, ÀÌÇÏ COVID-19)´Â ÁßÁõ ±Þ¼º È£Èí±â ½Åµå·Ò Äڷγª¹ÙÀÌ·¯½º 2 (Severe Acute Respiratory Syndrome Coronavirus 2, ÀÌÇÏ SARS-CoV-2)¿¡ ÀÇÇØ ¹ß»ýÇϴ ȣÈí±â ÁúȯÀ¸·Î 2019³â ù ¹ßº´ÀÌ º¸°íµÈ ÀÌÈÄ ÇöÀç±îÁö 3¾ï 7õ¸íÀÌ ³Ñ´Â È®ÁøÀÚ¿Í 5¹é6½Ê5¸¸¿©¸íÀÇ »ç¸ÁÀÚ¸¦ ÃÊ·¡ÇÑ Àü¼¼°èÀûÀÎ ´ëÀ¯Çà(pandermic) Áúº´ÀÌ´Ù (2022³â 2¿ù 1ÀÏ ±âÁØ) [1]. ±×³ª¸¶ ÃÖ±Ù SARS-CoV-2¿¡ ´ëÇÑ ¹é½ÅÀÌ º¸±ÞµÇ°í ¸î °¡Áö Ä¡·áÁ¦ÀÇ °³¹ß·Î ÀÎÇØ ±×µ¿¾ÈÀÇ ¹æ¿ª ½Ã½ºÅÛÀ» ÅëÇÑ ´ëÀÀ ¹æ½Ä¿¡ ´õÇØ º¸´Ù Àû±ØÀûÀÎ COVID-19 ´ëÀÀÀÌ °¡´ÉÇØÁö°í ÀÖ±â´Â ÇÏÁö¸¸ ¿À¹ÌÅ©·Ð, ½ºÅÚ½º ¿À¹ÌÅ©·Ð µîÀÇ º¯ÀÌ ÃâÇöÀ¸·Î ÀÎÇØ ¿©ÀüÈ÷ ¿ì¸®´Â COVID-19 ´ëÀ¯Çà »óȲ¿¡¼­ ¹þ¾î³ªÁö ¸øÇÏ°í ÀÖ´Ù. ±×°£ ¼ö¸¹Àº ¿¬±¸ÀÚµéÀÌ SARS-CoV-2¿Í COVID-19¿¡ ´ëÇÑ ´Ù¾çÇÑ »ý¹°ÇÐÀû/ÀÇÇÐÀûÀΠƯ¼ºµéÀ» ¹àÇô³ÂÁö¸¸ COVID-19 ±Øº¹À» À§Çؼ­´Â ¿©ÀüÈ÷ ´õ ¸¹Àº °úÇÐÀûÀÎ ÀÌÇØ°¡ ÇÊ¿äÇÏ´Ù.
   ¸¶ÀÌÅ©·Î¹ÙÀÌ¿ÈÀº ¹Ì»ý¹°µé·Î ÀÌ·ç¾îÁø »ýÅÂȯ°æÀ» ÀǹÌÇϴµ¥, ÀÎü¸¦ ±¸¼ºÇÏ´Â ¼¼Æ÷ÀÇ ¼ýÀÚº¸´Ù ´õ ¸¹Àº ¼öÀÇ ¹Ì»ý¹°ÀÌ ¿ì¸®ÀÇ ¸ö¿¡ °ÅÁÖÇÏ°í ÀÖÀ¸¸ç ±× Á¾·ùµµ 5000¿© Á¾ÀÌ ³Ñ´Â´Ù°í ¾Ë·ÁÁ® ÀÖ´Ù [2]. ±× Áß¿¡¼­ ¾ÐµµÀûÀ¸·Î ¸¹Àº ¼öÀÇ ¹Ì»ý¹°µéÀÌ À§Àå°ü¿¡ °ÅÁÖÇÏ°í ÀÖÀ¸¸ç, À̵éÀº À§Àå°ü¿¡¼­ ¹ß»ýÇÏ´Â ¸é¿ª¹ÝÀÀÀ̳ª Áúȯ»Ó¸¸ ¾Æ´Ï¶ó Àå-³ú Ãà(gut-brain axis), Àå-°£(gut-liver axis), Àå-Æó Ãà(gut-lung axis)¶ó´Â Ç¥ÇöÀÌ ³ª¿Ã¸¸Å­ ³ú, °£, Æó µî ÀÎü ´ëºÎºÐÀÇ Àå±â¿¡¼­ ¹ß»ýÇÏ´Â Áúȯ¿¡µµ ¿µÇâÀ» ÁÖ°í¹Þ´Â °ÍÀÌ Àß ¾Ë·ÁÁ® ÀÖ´Ù [2].
   COVID-19ÀÇ Àå³» ¸¶ÀÌÅ©·Î¹ÙÀÌ¿È¿¡ ´ëÇÑ ¿µÇâÀ̳ª Àå³» ¸¶ÀÌÅ©·Î¹ÙÀÌ¿È¿¡ ÀÇÇÑ COVID-19 ÁúȯÀÇ ¿µÇâ¿¡ ´ëÇÑ ¿¬±¸°¡ ¾ÆÁ÷ Ãʱ⠼öÁØÀ̱â´Â ÇÏÁö¸¸, º» ³í´Ü¿¡¼­´Â ¸¶ÀÌÅ©·Î¹ÙÀÌ¿È °üÁ¡¿¡¼­ COVID-19¸¦ ¹Ù¶óº¸´Â ¿¬±¸ °á°ú¸¦ ¼Ò°³ÇÔÀ¸·Î½á COVID-19¸¦ ±Øº¹Çϱâ À§ÇÑ º¸´Ù Æø ³ÐÀº °üÁ¡°ú Á¢±ÙÀÇ Çʿ伺À» Á¦¾ÈÇÏ°íÀÚ ÇÑ´Ù.

✓ COVID-19 ȯÀÚÀÇ Àå³» ¸¶ÀÌÅ©·Î¹ÙÀÌ¿ÈÀÇ º¯È­

  SARS-CoV-2 °¨¿° ½Ã È£Èí±â»Ó¸¸ ¾Æ´Ï¶ó ¼ÒÈ­±âÀÎ À§Àå°ü¿¡¼­µµ ÇØ´ç ¹ÙÀÌ·¯½º°¡ °ËÃâµÇ´Âµ¥, °¨¿° ÈÄ ¾à 40¿©ÀϱîÁö ºÐº¯¿¡¼­ ¹ÙÀÌ·¯½ºÀÇ RNA°¡ °ËÃâµÇ¸ç, º´Áõ ÇØ¼Ò ÀÌÈÄ 90ÀϱîÁö Àå »óÇǼ¼Æ÷¿¡¼­ SARS-CoV-2 ¹ÙÀÌ·¯½º°¡ °ËÃâµÇ´Â µî ¼ÒÈ­±â´Â SARS-CoV-2 °¨¿°À¸·Î ÀÎÇØ »ó´ç±â°£ ¿µÇâÀ» ¹Þ´Â´Ù [3, 4]. ½ÇÁ¦ COVID-19 ȯÀÚÀÇ ¾à Àý¹Ý Á¤µµ°¡ È£Èí±â Áõ»ó¿¡ ¾Õ¼­ ¼ÒÈ­±â Áõ¼¼¸¦ µ¿¹ÝÇÏ´Â °ÍÀ¸·Î º¸°íµÇ°í ÀÖ´Ù [5]
  Àå³» ¸¶ÀÌÅ©·Î¹ÙÀ̿ȵµ SARS-CoV-2 °¨¿°À¸·Î ÀÎÇØ ¿µÇâÀ» ¹Þ°Ô µÇ´Âµ¥, COVID-19 ȯÀÚ ºÐº¯À¸·ÎºÎÅÍ ¸¶ÀÌÅ©·Î¹ÙÀÌ¿ÈÀÇ ±¸¼ºÀ» ºÐ¼®ÇÑ º¸°í¸¦ »ìÆ캸¸é °Ç°­ÇÑ »ç¶÷µé°ú´Â ¸íÈ®È÷ ´Þ¶óÁ® ÀÖÀ½À» ¾Ë ¼ö ÀÖ´Ù. SARS-CoV-2 °¨¿° Ãʱ⳪ ȸº¹±â, ȸº¹Èı⿡ °ÉÃÄ Àå³» ¸¶ÀÌÅ©·Î¹ÙÀÌ¿ÈÀ» ±¸¼ºÇÏ°í ÀÖ´Â Á¾ÀÇ ´Ù¾ç¼ºÀÌ °¨¼ÒµÇ¾î ÀÖÀ¸¸ç [7], ƯÈ÷ ȸº¹Èı⿡ Á¾ ´Ù¾ç¼ºÀÌ ³·Àº ȯÀÚÀϼö·Ï COVID-19 Áõ¼¼°¡ ½É°¢ÇÏ°í °¨¿°Ãʱâ Ç÷¾×¿¡¼­ ¿°Áõ Á¤µµ¸¦ ÀǹÌÇÏ´Â C-reactive protein (CRP) °ªÀÌ ³ôÀº °æÇâÀ» ³ªÅ¸³Â´Ù [7]. ÀϹÝÀûÀ¸·Î Àå³» ¹Ì»ý¹°ÀÇ Á¾´Ù¾ç¼ºÀÌ ³ôÀ»¼ö·Ï ±âȸ°¨¿°À» ÀÏÀ¸Å°´Â À¯ÇرÕ(pathobiont)ÀÇ Áõ½ÄÀÌ ¾ïÁ¦µÇ´Â È¿°ú¸¦ °®°Ô µÇ´Âµ¥ [6], COVID-19 ȯÀÚµµ ¿ª½Ã ¸¶ÀÌÅ©·Î¹ÙÀÌ¿ÈÀÇ Á¾ ´Ù¾ç¼ºÀÌ ³·À» »Ó ¾Æ´Ï¶ó ±âȸ°¨¿°¼º À¯ÇرÕÀº Áõ°¡ÇÏ°í ÀϹÝÀûÀ¸·Î À¯ÀÍÇÑ È¿°ú¸¦ ³ªÅ¸³½´Ù°í ¾Ë·ÁÁø À¯ÀͱÕ(symbiont)ÀÇ ºñÀ²Àº °¨¼ÒÇÔÀÌ °üÂûµÇ¾ú´Ù. ±¸Ã¼ÀûÀ¸·Î Faecalibacterium prausnitzii, Clostridium butyricum, Clostridium leptum, Eubacterium rectale°ú °°Àº ªÀº »ç½½ Áö¹æ»ê(short chain fatty acid, ÀÌÇÏ SCFA)ÀÇ ÇÑ Á¾·ùÀÎ Butyrate¸¦ »ý»êÇÏ´Â ¼¼±ÕÀÇ ¾çÀº COVID-19 ȯÀÚ¿¡°Ô¼­ Çö°ÝÈ÷ ÁÙ¾îµé¾úÀ¸¸ç, Enterobacteriaceae¿Í Enterococcus¿Í °°Àº ±âȸ°¨¿° ¼¼±ÕÀº Áõ°¡ÇÏ¿´´Ù [8]. ´Ù¸¥ ³í¹®¿¡¼­µµ ±âȸ°¨¿° À¯ÇرÕÀÎ Streptococcus, Rothia, Veillonella, Actinomyces ¼Ó(genera)ÀÌ COVID-19 ȯÀÚ ºÐº¯¿¡¼­ »ó´ëÀûÀ¸·Î dzºÎÇϸç, ±×¿¡ ¹ÝÇØ °Ç°­ÇÑ »ç¶÷ÀÇ ºÐº¯¿¡´Â Romboutsia, Faecalibacterium, Fusicatenibacter ¼ÓÀÌ ¸¹ÀÌ ºÐÆ÷ÇÏ´Ù´Â °ÍÀÌ º¸°íµÇ¾ú´Ù [9].
  COVID-19 Áõ¼¼¿¡ µû¸¥ ºÐ¼® °á°ú¸¦ »ìÆ캸¸é ¸¶ÀÌÅ©·Î¹ÙÀÌ¿ÈÀÇ ±¸¼ºÀÌ COVID-19 º´ÁõÀÇ ½É°¢µµ¿Íµµ °ü·ÃÀÌ ÀÖÀ½À» ¾Ë ¼ö ÀÖ´Ù. Áï, COVID-19 ȯÀÚÀÇ ¿°Áõ¼º »çÀÌÅäÄ«Àΰú ¿°Áõ¼º ÀÎÀÚÀÎ CRP, ¼¼Æ÷ ¼Õ»óÁ¤µµ¸¦ º¸´Â lactate dehydrogenase, °£ ¼Õ»ó ¼öÄ¡ÀÎ aspartate aminotransferase (AST)¿Í gamma-glutamyl transferase (GGT) µîÀÇ °ª¿¡ µû¶ó ¸¶ÀÌÅ©·Î¹ÙÀÌ¿ÈÀÇ ±¸¼º¿¡´Â Â÷ÀÌ°¡ ³ªÅ¸³µ´Ù [10]. ƯÈ÷ COVID-19ÀÇ Áõ¼¼°¡ ½É°¢ÇØÁú¼ö·Ï Coprobacillus, Clostridium ramosum, Clostridium hathewayi¿Í °°Àº ±âȸ°¨¿° ¼¼±ÕÀÌ Áõ°¡ÇÏ´Â Ãß¼¼¿¡ ÀÖÀ¸¸ç, ±×¿¡ ¹ÝÇØ Ç׿°Áõ ±â´ÉÀ» °®´Â °ÍÀ¸·Î ¾Ë·ÁÁø F. prausnitzii µîÀº »ó´ëÀûÀ¸·Î COVID-19 Áõ¼¼°¡ ½É°¢ÇÏÁö ¾ÊÀº ȯÀÚ¿¡°Ô¼­ ´õ ¸¹ÀÌ ¹ß°ßµÇ¾ú´Ù [11].
  ÀÌ·¯ÇÑ COVID-19 ȯÀÚ¿¡¼­ ³ªÅ¸³­ Àå³» ¸¶ÀÌÅ©·Î¹ÙÀÌ¿ÈÀÇ º¯È­´Â µ¿¹° ¸ðµ¨À» ÅëÇÑ ¿¬±¸¿¡¼­µµ Áõ¸íµÇ¾ú´Ù. ¸¶¿ì½º¸¦ ´ë»óÀ¸·Î ÇÑ SARS-CoV-2 °¨¿° ½ÇÇè ³»¿ëÀ» »ìÆ캸¸é Àå »óÇǼ¼Æ÷¿¡¼­ ¸é¿ªÀ̳ª °¨¿° °ü·ÃµÈ À¯ÀüÀÚÀÇ Áõ°¡°¡ °üÂûµÇ¾úÀ¸¸ç, ÀÌ·¯ÇÑ Àå³» ȯ°æÀÇ º¯È­°¡ Àå³» ¸¶ÀÌÅ©·Î¹ÙÀÌ¿ÈÀÇ ±¸¼º¿¡µµ º¯È­¸¦ ¾ß±âÇÔÀÌ °üÂûµÇ¾ú´Ù [12]. ¿µÀå·ù µ¿¹° ¸ðµ¨(rhesus macaques¿Í cynomolgus macaques)À» »ç¿ëÇÑ SARS-CoV-2 °¨¿° °á°ú¿¡¼­µµ °¨¿° ÀÌÈÄ Á¡Â÷ Àå³» ¸¶ÀÌÅ©·Î¹ÙÀÌ¿È ±¸¼ºÀÌ ´Þ¶óÁ³´Âµ¥, COVID-19 ȯÀÚ¿¡°Ô¼­ ¹ß°ßµÈ °Í°ú ¸¶Âù°¡Áö·Î Proteobacteria ¹®(phylum)¿¡ ¼ÓÇÏ´Â ±âȸ°¨¿°¼º À¯ÇرÕÀÇ ¾çÀº ´Ã¾î³ª°í Firmicutes ¹®¿¡ ¼ÓÇÏ´Â À¯ÀͱÕ(Ruminococcaceae¿Í Lachnospiraceae °­(family))ÀÇ ¾çÀº °¨¼ÒÇÏ¿´´Ù [13]. ÀÌ·¯ÇÑ °á°úµéÀº SARS-CoV-2 °¨¿°À¸·Î ÀÎÇÑ ¸é¿ªº´¸®ÇÐÀûÀÎ º¯È­°¡ ȯÀÚÀÇ Àå³» ¸¶ÀÌÅ©·Î¹ÙÀÌ¿È ±¸¼ºÀÇ º¯È­¸¦ ÃÊ·¡ÇÑ´Ù´Â °ÍÀ» º¸¿©ÁØ´Ù.

✓ COVID-19 ȯÀÚÀÇ Àå³» Mycobiome°ú Virome

  ¸¶ÀÌÅ©·Î¹ÙÀÌ¿ÈÀº ¸ðµç ¹Ì»ý¹°·Î ÀÌ·ç¾îÁø »ýÅ°踦 À̾߱âÇÏÁö¸¸ ¸¶ÀÌÅ©·Î¹ÙÀÌ¿ÈÀÇ Àý´ë ´Ù¼ö´Â ¼¼±Õ(bacteria)ÀÌ°í ¿¬±¸ ¹æ¹ý·ÐÀÇ ÇѰ質 ¿ëÀ̼º ¶§¹®¿¡ ÁÖ·Î ¼¼±ÕÀ» ´ë»óÀ¸·Î À̾߱âÇÏ´Â °æ¿ì°¡ ¸¹´Ù. ÇÏÁö¸¸ »ç¶÷ÀÇ Àå³»¿¡´Â »ó´ç ¼öÀÇ °õÆÎÀÌ(fungi)¿Í RNA/DNA ¹ÙÀÌ·¯½ºµµ Á¸ÀçÇϸç À̵éÀº ¼¼±Õ ¸¶ÀÌÅ©·Î¹ÙÀÌ¿ÈÀÇ ±¸¼ºÀ̳ª ¼÷ÁÖÀÇ ¸é¿ª½Ã½ºÅÛ ¹ß´Þ¿¡µµ Áß¿äÇÑ ¿ªÇÒÀ» ÇÑ´Ù°í ¾Ë·ÁÁ® ÀÖ´Ù [14]. ¸¶ÀÌÅ©·Î¹ÙÀÌ¿È Áß¿¡¼­µµ °õÆÎÀÌ·Î ÀÌ·ç¾îÁø ±ºÁýÀ» Mycobiome, ¹ÙÀÌ·¯½º ±ºÁýÀ» ViromeÀÌ¶ó ±¸ºÐÇؼ­ ÁöĪÇϱ⵵ ÇÑ´Ù.
  COVID-19ÀÇ È¯ÀÚ ºÐº¯Àº Mycobiome¿¡¼­µµ Ư¡ÀûÀ¸·Î Â÷ÀÌ°¡ ³ªÅ¸³­´Ù. COVID-19 ȯÀÚ¿¡°Ô´Â °õÆÎÀÌÀÇ 2Â÷ °¨¿°À̳ª µ¿½Ã °¨¿°ÀÌ ÈçÈ÷ °üÂûµÇ¸ç, ±âȸ°¨¿°¼º °õÆÎÀÌ º´¿ø±ÕÀÎ Candida albicans, Candida auris, Aspergillus flavus µîÀÌ Áúº´ ±â°£ µ¿¾È Áõ°¡Çϸç ÀϺδ º´Áõ ȸº¹ ÀÌÈıîÁö ¸¹ÀÌ °ËÃâµÇ´Â °ÍÀ¸·Î º¸°í µÇ¾ú´Ù [15]. ÀÌ·¯ÇÑ COVID-19 ȯÀÚ¿¡°Ô¼­ Ư¡ÀûÀ¸·Î Áõ°¡ÇÏ´Â °õÆÎÀ̵éÀº Æó·Å°ú °°Àº È£Èí±â Áõ¼¼¿Í °ü·ÃÀÌ Àְųª ¿°Áõ ÁöÇ¥ÀÇ Áõ°¡³ª ¼³»ç Áõ¼¼¿Íµµ °ü·ÃÀÌ ÀÖ´Â °ÍÀ¸·Î ¾Ë·ÁÁ® ÀÖ´Ù [15]. C. albicansÀÇ °æ¿ì´Â Àå³» ¸¶ÀÌÅ©·Î¹ÙÀÌ¿ÈÀÇ ¾ÈÁ¤È­¿¡ ¾Ç¿µÇâÀ» ¹ÌÃÄ Ç×»ýÁ¦ 󸮳ª ¿°ÁõÀ¸·Î ÀÎÇØ ¸Á°¡Áø ¸¶ÀÌÅ©·Î¹ÙÀÌ¿ÈÀÌ È¸º¹µÇ´Â °ÍÀ» ¹æÇØÇÏ´Â °ÍÀ¸·Îµµ ¾Ë·ÁÁ® ÀÖ´Ù [16]. ÀÌ´Â Àå³» ¸¶ÀÌÅ©·Î¹ÙÀÌ¿È »ýÅ°迡 À־ ¹Ì»ý¹° °è(kingdom) °£ÀÇ »óÈ£ÀÛ¿ëµµ Áß¿äÇÒ ¼ö ÀÖÀ½À» ÀǹÌÇÑ´Ù.
  Àå³» ViromeÀ» ±¸¼ºÇÏ´Â ¹ÙÀÌ·¯½º´Â ¼÷ÁÖ¸¦ Ÿ°ÙÀ¸·Î ÇÏ´Â °Í°ú ¼¼±ÕÀ» Ÿ°ÙÀ¸·Î ÇÏ´Â °ÍÀ¸·Î ±¸ºÐÇÒ ¼ö ÀÖ´Ù. ¼÷ÁÖ¸¦ Ÿ°ÙÀ¸·Î ÇÏ´Â ¹ÙÀÌ·¯½º´Â ¼÷ÁÖ ¸é¿ª ½Ã½ºÅÛ¿¡ ¿µÇâÀ» ¹ÌÄ¡°Ô µÇ°í ¼¼±ÕÀ» Ÿ°ÙÀ¸·Î ÇÏ´Â ¹ÙÀÌ·¯½º(¹ÚÅ׸®¿ÀÆÄÁö)´Â Àå³» ¼¼±ÕµéÀÇ ±¸¼º¿¡ ¿µÇâÀ» ¹ÌÄ¡°Ô µÈ´Ù. COVID-19 ȯÀÚÀÇ °æ¿ì ¼÷ÁÖ¸¦ Ÿ°ÙÀ¸·Î ÇÏ´Â ¹ÙÀÌ·¯½º°¡ »ó´ëÀûÀ¸·Î ¸¹ÀÌ Á¸ÀçÇϴµ¥ À̵éÀº ÀÎüÀÇ ¸é¿ª ±â´ÉÀÇ Àå¾Ö¸¦ ÃÊ·¡Çϴµ¥ ±â¿©ÇÒ °ÍÀ¸·Î »ý°¢µÈ´Ù [17, 18]. ¶ÇÇÑ ¹ÚÅ׸®¿ÀÆÄÁö°¡ ´Ù¾çÇÒ¼ö·Ï COVID-19 º´ÁõÀÇ ½É°¢¼ºÀº °¨¼ÒÇÏ´Â °æÇâÀ» º¸ÀÌ°í ÀÖ´Ù [17]. COVID-19 ȯÀÚ ViromeÀÇ ÁÖ¿ä ¿ìÁ¡Á¾Àº Escherichia phage¿Í Enterobacter phageÀ̸ç Ÿ°ÙÀÌ µÇ´Â ¼¼±ÕÀÇ ¾çµµ µ¿½Ã¿¡ ´Ã¾î³ª´Â Ư¡ÀÌ º¸À̴µ¥, ÀÌ°ÍÀº COVID-19 º´ÁõÀÎ °úµµÇÑ ¿°Áõ »óȲÀ¸·Î ÀÎÇØ ÇØ´ç ¼¼±ÕÀÌ ºÐÇصǸ鼭 °¢ ÆÄÁöµµ °°ÀÌ Áõ½Ä ¹× ÀüÆÄ°¡ ÀÌ·ç¾îÁö±â ¶§¹®À¸·Î º¸Àδ٠[17, 19]. ÀÌó·³ ¼¼±Õ ÀÌ¿Ü¿¡ °õÆÎÀ̳ª ¹ÙÀÌ·¯½º¿Í °°Àº ¹Ì»ý¹°µéÀº ¼÷ÁÖ¿ÍÀÇ »óÈ£ÀÛ¿ë ±×¸®°í ¹Ì»ý¹°µé °£ÀÇ »óÈ£ÀÛ¿ëÀÌ º¹ÀâÇÏ°Ô ¾ôÇôÀÖÀ¸¸ç °á°úÀûÀ¸·Î ÀÌ·¯ÇÑ º¹ÀâÇÑ ³×Æ®¿öÅ©°¡ COVID-19 º´Áõ Á¤µµ¿¡µµ Áß¿äÇÑ ¿µÇâÀ» ÁÖ°í ¹Þ´Â °ÍÀ¸·Î º¸¿©Áø´Ù.

✓ COVID-19 º´Áõ¿¡ ´ëÇÑ Àå³» ¸¶ÀÌÅ©·Î¹ÙÀÌ¿ÈÀÇ ÀÛ¿ë±âÀü

  È£Èí±â³ª ¼ÒÈ­±âÀÇ »óÇÇ ¼¼Æ÷ Ç¥¸é¿¡ ¸¹ÀÌ ¹ßÇöµÇ´Â Angiotensin-converting enzyme 2 (ACE2)´Â SARS-CoV-2°¡ ¼÷ÁÖ¿¡ µé¾î°¡±â À§ÇÑ °áÇÕ ¼ö¿ëü·Î ACE2ÀÇ ¹ßÇö·®ÀÌ COVID-19 Áõ¼¼¿Í ¹ÐÁ¢ÇÑ »ó°ü°ü°è¸¦ °®´Â´Ù´Â °ÍÀÌ Àß ¾Ë·ÁÁ® ÀÖ´Ù. ƯÈ÷ °í·ÉÃþ¿¡¼­ÀÇ COVID-19 Áõ¼¼°¡ ½É°¢ÇÑ ¿øÀÎ Áß Çϳª·Î °í·ÉÃþ¿¡ ACE2ÀÇ ¹ßÇöÀÌ ³ôÀº °Íµµ Áß¿äÇÑ ¿øÀÎÀ¸·Î Áö¸ñµÇ°í ÀÖ´Ù [22]. ACE2´Â ¾Æ¹Ì³ë»êÀ» ¼¼Æ÷ ¾ÈÀ¸·Î ¼ö¼ÛÇÏ´Â ¿ªÇÒÀ» Çϱ⠶§¹®¿¡ ü³» ¾Æ¹Ì³ë»êÀÇ Ç×»ó¼º À¯Áö¿¡ Áß¿äÇÑ ¿ªÇÒÀ» ÇÑ´Ù. ¶ÇÇÑ ÀÌ·¯ÇÑ ¾Æ¹Ì³ë»ê ¼ö¼ÛÀº renin-angiotensin system (RAS)¸¦ ÅëÇØ Àå»óÇǼ¼Æ÷¿¡¼­´Â Ç׹̻ý¹° ÆéƼµå(anti-microbial peptide)ÀÇ ¹ßÇöÀ» Á¶ÀýÇÏ´Â ¿ªÇÒÀ» Çϱ⠶§¹®¿¡ Àå³» ¸¶ÀÌÅ©·Î¹ÙÀÌ¿È ±¸¼º¿¡µµ ¿µÇâÀ» ¹ÌÄ¡°Ô µÈ´Ù [23]. ¹Ý´ë·Î ¸¶ÀÌÅ©·Î¹ÙÀ̿ȵµ ACE2¿¡ ¿µÇâÀ» ¹ÌÄ¥ ¼ö ÀÖ´Ù. ¹«±Õ »ýÁã¿Í SPF(specific patogen free) ¸¶¿ì½º¿¡¼­ÀÇ ACE2 ¹ßÇö·®À» ºñ±³ÇÑ ¿¬±¸ °á°ú¸¦ ÅëÇØ Àå³» ¸¶ÀÌÅ©·Î¹ÙÀÌ¿ÈÀÌ ACE2ÀÇ ¹ßÇö¿¡ ¿µÇâÀ» ¹ÌÄ¥ ¼ö ÀÖ´Ù´Â °ÍÀÌ Áõ¸íµÇ¾úÀ¸¸ç, ¸¶ÀÌÅ©·Î¹ÙÀÌ¿È Áß¿¡¼­µµ protease¿Í peptidase¸¦ »ý»êÇÏ´Â ¹Ì»ý¹°ÀÇ ¾çÀÌ Áõ°¡ÇÒ¼ö·Ï ACE2ÀÇ ¹ßÇöÀÌ Áõ°¡ÇÑ´Ù´Â °ÍÀÌ º¸°íµÇ¾îÀÖ´Ù [24]. ÀÌó·³ ACE2´Â SARS-CoV-2 ħÀÔÀ» ¸Å°³ÇÒ »Ó¸¸ ¾Æ´Ï¶ó COVID-19 º´Áõ Á¤µµ¿Í Àå³» ¸¶ÀÌÅ©·Î¹ÙÀÌ¿ÈÀÇ °ü·Ã¼ºÀ» ¸Å°³ÇÏ´Â Áß¿äÇÑ ºÐÀÚ Áß Çϳª·Î »ý°¢µÈ´Ù.
  SARS-CoV-2 °¨¿°¿¡ ´ëÇÑ ÀÎüÀÇ ¸é¿ª ¹ÝÀÀÀº °úµµÇÑ ¿°Áõ ¹ÝÀÀÀ» µ¿¹ÝÇÏ°Ô µÇ¸ç °á°úÀûÀ¸·Î À庮ÀÇ Åõ°úµµ¿¡ ¹®Á¦¸¦ ÀÏÀ¸Å²´Ù [20]. ´Ù½Ã ¸»ÇØ °úµµÇÑ ¿°ÁõÀº Àå ´©¼ö(leaky gut) »óŸ¦ ¸¸µé°Ô µÇ°í, ÀÌ´Â Àå³» ¸¶ÀÌÅ©·Î¹ÙÀÌ¿ÈÀÌ »ý»êÇÑ »ê¹°À̳ª µ¶¼Ò(toxin) µîÀÌ ¸ö ¾ÈÀ¸·Î ´©ÃâµÇ´Â »óȲÀ» ¾ß±âÇÏ´Â °ÍÀÌ´Ù (±×¸² 1). COVID-19 ½É°¢µµ°¡ ³·Àº °æ¿ì Bacteroidetes ¹®¿¡ ¼ÓÇÏ´Â Alistipes onderdonkii¿Í Bacteroides ovatus µîÀÇ ºñÀ²ÀÌ ³ô´Ù°Å³ª, Bacteroides dorei, Bacteroides thetaiotaomicron, Bacteroides massiliensis, Bacteroides ovatusÀÇ Á¸Àç°¡ ȯÀÚ ºÐº¯¿¡¼­ °ËÃâµÇ´Â SARS-CoV-2 ¹ÙÀÌ·¯½º¾ç°ú ¿ªºñ·Ê °ü°è¸¦ °®´Â°ÍÀ¸·Î ¾Ë·ÁÁ® Àִµ¥ [11], B. dorei¿Í Bacteroides vulgatus´Â Àå³» ¹Ì»ý¹°¿¡ ÀÇÇÑ LPSÀÇ »ý»êÀ» ¾ïÁ¦ÇÏ´Â °ÍÀ¸·Î ¾Ë·ÁÁ® ÀÖ¾î COVID-19 ȯÀÚÀÇ Àå ´©¼ö »óȲ¿¡¼­ COVID-19 º´ÁõÀÇ ½É°¢¼ºÀÌ ºñ±³Àû ¾àÇÑ °ÍÀ» ¼³¸íÇÒ ¼ö ÀÖ´Ù [21].
  COVID-19´Â ÆóÁúȯÀÌÁö¸¸ Àå³» ¸¶ÀÌÅ©·Î¹ÙÀÌ¿ÈÀº ÆóÀÇ Áõ¼¼¿¡ ¿µÇâÀ» ¹ÌÄ¥ ¼ö ÀÖÀ¸¸ç ÀÌ·¯ÇÑ ¿µÇâÀ» Àå-Æó ÃàÀ̶ó´Â Ç¥ÇöÀ¸·Î À̾߱âÇÑ´Ù. ¾Õ¼­ ¾ð±ÞÇÑ ¹Ù¿Í °°ÀÌ Àå ´©¼ö·Î ÀÎÇØ Àå³» ¹Ì»ý¹°ÀÇ »ê¹°ÀÌ ´©ÃâµÇ¾î Ç÷¾×À» µû¶ó Æó¿¡ µµ´ÞÇÏ¿© ¿µÇâÀ» ¹ÌÄ¥ ¼öµµ ÀÖÁö¸¸ Àå³» ¸¶ÀÌÅ©·Î¹ÙÀÌ¿È¿¡ ÀÇÇؼ­ »ý»êµÇ´Â ´ë»çü(metabolite)µµ Àå»óÇÇ À庮À» ³Ñ¾î¼­ Àü½ÅÀ» ¼øȯÇÏ¿© Æó¿¡¼­ ÀϾ´Â ¸é¿ª ¹ÝÀÀ¿¡ ¿µÇâÀ» ¹ÌÄ¥ ¼ö ÀÖ´Ù (±×¸² 1). ¿©·¯ ´ë»çü Áß SCFA´Â ÁÖ·Î À½½ÄÀÇ ¼¶À¯ÁúÀ» ¼¼±ÕÀÌ ¹ßÈ¿ÇÏ¿© ¸¸µé¾îÁö¸ç, ¿°Áõ°ú ¾Ë·¹¸£±â ¹ÝÀÀ µîÀ» ¿ÏÈ­ÇÏ´Â È¿°ú°¡ ¾Ë·ÁÁ® ÀÖ´Ù. ¿µÀå·ù¸¦ ´ë»óÀ¸·Î ÇÑ SARS-CoV-2 °¨¿° ¸ðµ¨¿¡¼­µµ ºÐº¯ ³» SCFA°¡ ³·¾ÆÁüÀÌ °üÂûµÇ¾ú´Ù [13]. ÀÌ´Â COVID-19 ȯÀÚ¿¡¼­ °üÂûµÈ °á°ú¿Íµµ ÀÏÄ¡Çϴµ¥, ȯÀÚÀÇ ºÐº¯¿¡´Â SCFA¸¦ »ý»êÇÏ´Â ¼¼±ÕÀÌ °¨¼Ò¾î ÀÖÀ¸¸ç ´õºÒ¾î SCFAÀÇ Ç÷Áß ³óµµµµ °¨¼ÒµÇ¾î ÀÖ¾ú´Ù. ¶ÇÇÑ °¨¿°·ÂÀÌ ³ôÀº SARS-CoV-2¿¡ °¨¿°µÈ ȯÀÚ¿¡ ºñÇØ °¨¿°·ÂÀÌ ³·Àº ¹ÙÀÌ·¯½º¸¦ °®´Â ȯÀÚÀÇ °æ¿ì SCFA¸¦ »ý»êÇÏ´Â ¼¼±ÕÀÎ Alistipes onderdonkii, Parabacteroides merdae, Bacteroides stercoris, Lachnospiracease bacterium 1_1_57FAA µîÀÇ ºñÀ²ÀÌ »ó´ëÀûÀ¸·Î ³ô¾Ò´Ù [25]. ³·Àº °¨¿°¼ºÀ» °®´Â SARS-CoV-2 °¨¿° ȯÀÚ¿¡¼­ ¸¹ÀÌ °ËÃâµÇ´Â Alistipes onderdonkiiÀº indole »ý»ê ¾ç¼º ¼¼±ÕÀ¸·Î Æ®¸®ÅäÆÇ ´ë»ç¸¦ ÅëÇØ Àå³» ¸é¿ª Ç×»ó¼º À¯Áö¿¡ °ü¿©ÇÏ´Â °ÍÀ¸·Îµµ ¾Ë·ÁÁ® ÀÖ´Ù [26]. ±×¿¡ ¹ÝÇØ ¸¶ÀÌÅ©·Î¹ÙÀÌ¿ÈÀÇ Æ®¸³ÅäÆÇ ´ë»çü Áß ÇϳªÀÎ TryptamineÀÇ ¾çÀº SARS-CoV-2 °¨¿°µÈ ¿µÀå·ù¿¡¼­ Áõ°¡µÇ¾î ÀÖÀ¸¸ç, ¶Ç ´Ù¸¥ Æ®¸³ÅäÆÇ ´ë»ç »ê¹°ÀÎ quinolinic acid¿Í picolinic acids µµ COVID-19 ȯÀÚ¿¡°Ô¼­ Áõ°¡Çϴµ¥ ÀÌ´Â Àå³» ¿°Áõ ¹ß»ýÀ» ÀǹÌÇÑ´Ù [13, 27]. ÀÌó·³ SARS-CoV-2 °¨¿°À» ÅëÇØ º¯È­ÇÑ Àå³» ¸¶ÀÌÅ©·Î¹ÙÀÌ¿È°ú ´õºÒ¾î ³ªÅ¸³ª´Â ´ë»çüÀÇ Áõ°¨Àº Àå-Æó »óÈ£ÀÛ¿ëÀÇ Áß¿äÇÑ ÀÛ¿ë ±âÀüÀ¸·Î »ý°¢µÇ¸ç, °á°úÀûÀ¸·Î COVID-19 º´Áõ¿¡ Áß¿äÇÑ ¿µÇâÀ» ¹ÌÄ¡°Ô µÈ´Ù.

±×¸² 1. COVID-19 »óȲÀÇ Àå-¸¶ÀÌÅ©·Î¹ÙÀÌ¿È-Æó Ãà(axis) »óÈ£ÀÛ¿ë ¸ð½Äµµ.
±×¸² 1. COVID-19 »óȲÀÇ Àå-¸¶ÀÌÅ©·Î¹ÙÀÌ¿È-Æó Ãà(axis) »óÈ£ÀÛ¿ë ¸ð½Äµµ.
COVID-19´Â °úµµÇÑ ¿°ÁõÀ¸·Î ÀÎÇØ Àå³» ¸¶ÀÌÅ©·Î¹ÙÀÌ¿È ±¸¼º¿¡ ¿µÇâÀ» ¹ÌÄ¡¸ç, Àå¿¡´Â Àå ´©¼ö¸¦ ¹ß»ý½ÃŲ´Ù. Àå³» ¸¶ÀÌÅ©·Î¹ÙÀÌ¿ÈÀº Àå ´©¼ö·Î ÀÎÇØ µ¶¼Ò¿Í °°Àº ¹Ì»ý¹°ÀÌ ´©ÃâµÇ¾î Æó·Î µé¾î°¡ ¿°Áõ¹ÝÀÀÀ» °­È­½ÃÅ°°Å³ª ´ë»çü°¡ Àü½ÅÀ¸·Î ¼øȯÇϸ鼭 COVID-19 º´Áõ¿¡ ¿µÇâÀ» ³¢Ä£´Ù.

✓ ¸¶ÀÌÅ©·Î¹ÙÀÌ¿È ±â¹Ý COVID-19 ¿¹¹æ ¹× Ä¡·áÀÇ ÇÑ°è¿Í ÀáÀç·Â

  ¸¶Áö¸·À¸·Î ÀÌó·³ Áß¿äÇÑ Àå³» ¸¶ÀÌÅ©·Î¹ÙÀÌ¿ÈÀÇ Á¶ÀýÀ» ÅëÇÑ COVID-19 ¿¹¹æ ¹× Ä¡·á ¹æ½ÄÀÇ ÇÑ°è¿Í ÀáÀç·Â¿¡ ´ëÇؼ­ ¾Ë¾Æº¸ÀÚ (±×¸² 2).

±×¸² 2. ¸¶ÀÌÅ©·Î¹ÙÀÌ¿È ±â¹Ý Á¦Á¦ ¿ë¾î Á¤¸®.
±×¸² 2. ¸¶ÀÌÅ©·Î¹ÙÀÌ¿È ±â¹Ý Á¦Á¦ ¿ë¾î Á¤¸®.
»ì¾ÆÀÖ´Â À¯ÀͱÕÀÎ ÇÁ·Î¹ÙÀÌ¿Àƽ½º¸¦ Áß½ÉÀ¸·Î À̵éÀ» Àß ÀÚ¶ó°Ô Çϴµ¥ µµ¿òÀÌ µÇ´Â Á¦Á¦¸¦ ÇÁ¸®¹ÙÀÌ¿Àƽ½º¶ó Çϸç ÇÁ·Î¹ÙÀÌ¿Àƽ½º¿Í ÇÁ¸®¹ÙÀÌ¿Àƽ½º¸¦ ÇÕÃijõÀº °ÍÀ» ½Å¹ÙÀÌ¿Àƽ½º¶ó ÇÑ´Ù. ÇÁ·Î¹ÙÀÌ¿Àƽ½ºÀÇ À¯¿ë¹°Áú(´ë»çü Æ÷ÇÔ)À» Æ÷½ºÆ® ¹ÙÀÌ¿Àƽ½º¶óÇϸç, ÇÁ·Î¹ÙÀÌ¿Àƽ½º°¡ ÀǾàÇ° ¼öÁØÀÇ ½ÂÀÎÀ» ¹Þ°Ô µÇ¸é Æĸ¶¹ÙÀÌ¿Àƽ½º¶ó ºÒ¸°´Ù. FMT´Â °Ç°­ÇÑ »ç¶÷ÀÇ ´ëº¯À» À̽ÄÇÏ´Â °ÍÀ» ÀǹÌÇϸç, Àüü ¸¶ÀÌÅ©·Î¹ÙÀÌ¿ÈÀÇ ±¸¼º¿¡ ¿µÇâÀ» ¹ÌÄ¡´Â Ä¡·áÁ¦¸¦ Æĸ¶ÄÚ¸¶ÀÌÅ©·Î¹ÙÀÌ¿Àƽ½º¶ó ÇÑ´Ù.

  ¿ì¼± ÇÁ¸®¹ÙÀÌ¿Àƽ½º(prebiotics)¶õ À¯ÀͱÕÀÇ ¼ºÀå¿¡´Â ÇÊ¿äÇÏ°í À¯ÇرÕÀÇ ¼ºÀåÀº ¾ïÁ¦ÇÒ ¼ö ÀÖ´Â ÀÏÁ¾ÀÇ ¹Ì»ý¹°ÀÇ ¸ÔÀ̷νá À̸¦ Á¦Ç°È­ÇÑ »óÇ°ÀÌ ½ÃÁß¿¡µµ ¸¹ÀÌ ÆǸŵǰí ÀÖ´Ù. À½½Ä¹°ÀÇ ¼¶À¯ÁúÀº ´ëÇ¥ÀûÀÎ ÇÁ¸®¹ÙÀÌ¿Àƽ½º·Î ¾Ë·ÁÁ® ÀÖÀ¸¸ç, ¾Õ¼­µµ ¾ð±ÞÇÑ ¹Ù¿Í °°ÀÌ ¹Ì»ý¹°¿¡ ÀÇÇÑ SCFA »ý»êÀÇ ±â¹ÝÀÌ µÈ´Ù [2]. COVID-19 ȯÀÚ´Â SCFA¸¦ »ý»êÇÏ´Â °ÍÀ¸·Î ¾Ë·ÁÁø ¹Ì»ý¹°ÀÇ º¸À¯ ºñÀ²ÀÌ ÁÙ°í Ç÷¾×»ó SCFA ¼öÁصµ ³·¾ÆÁö±â ¶§¹®¿¡, ¼¶À¯Áú ÇÔ·®ÀÌ ³ôÀº À½½ÄÀ̳ª ¼¶À¯Áú Á¦Á¦¸¦ ÅëÇØ SCFA¸¦ »ý»êÇÏ´Â Àå³» À¯ÀͱյéÀÇ ºñÀ²À» ´Ã¸®±â À§ÇÑ ½Ãµµ¸¦ Çغ¼ ¼ö ÀÖÀ» °ÍÀÌ´Ù. ÇÏÁö¸¸ COVID-19°¡ ´ë°Ô ±Þ¼º ÁúȯÀε¥´Ù°¡ ¾ÆÁ÷±îÁö ½ÇÁ¦ ƯÁ¤ À½½ÄÀ̳ª ÇÁ¸®¹Ù¿Àƽ½º Á¦Á¦°¡ Á÷Á¢ÀûÀ¸·Î º´Áõ¿¡ µµ¿òÀÌ µÈ´Ù´Â °úÇÐÀûÀÎ ¿¬±¸ °á°ú´Â ¾ø±â ¶§¹®¿¡ ÇöÀç·Î½á´Â ÇÁ¸®¹ÙÀÌ¿Àƽ½ºÀÇ Á÷Á¢ÀûÀÎ COVID-19 Ä¡·á È¿°ú´Â ±â´ëÇϱ⠾î·Æ´Ù. ±»ÀÌ ÇÁ¸®¹Ù¿Àƽ½ºÀÇ ±àÁ¤ÀûÀÎ È¿°ú¸¦ ±â´ëÇغ¸ÀÚ¸é COVID-19 ÈÄÀ¯ÁõÀ¸·Î ³ªÅ¸³ª´Â ´Ù¾çÇÑ ¼ÒÈ­±â Áúȯ¿¡¼­ÀÇ ¸¶ÀÌÅ©·Î¹ÙÀÌ¿ÈÀÇ Á߿伺À» Á» ´õ °ËÁõÇÑ ÀÌÈÄ¿¡³ª ÇÁ·Î¹ÙÀÌ¿Àƽ½ºÀÇ È¿°ú¸¦ °ËÁõÇغ¼ °¡Ä¡°¡ »ý±âÁö ¾ÊÀ»±î »ç·áµÈ´Ù.
  ´ÙÀ½À¸·Î´Â ÇÁ·Î¹ÙÀÌ¿Àƽ½º(probiotics) Áï, À¯ÀÍÇÑ ¹Ì»ý¹°À» Á÷Á¢ »ç¿ëÇÏ´Â ¹æ½ÄÀÌ ÀÖÀ» ¼ö ÀÖ´Ù. ±âÁ¸¿¡ ´Ù¾çÇÑ È£Èí±â ¹ÙÀÌ·¯½º Áúȯ¿¡ À־ Lactobacillus °è¿­À̳ª Bifidobacterium °è¿­ÀÇ ¹Ì»ý¹°ÀÇ °æ±¸Åõ¿©°¡ À¯ÀǹÌÇÑ º¸È£ È¿°ú¸¦ °®´Â´Ù´Â °á°ú°¡ º¸°íµÇ¾î ÀÖ´Ù [28]. ¶ÇÇÑ COVID-19 ȯÀÚ¿¡°Ô¼­ Àå³» ¹Ì»ý¹°ÀÇ ºÒ±ÕÇüÀÌ ¹ß»ýÇÏ´Â »óȲÀÌ ¸íÈ®ÇÏ°í ÀÌ·Î ÀÎÇÑ º´ÁõÀÌ ½É°¢ÇØÁø´Ù´Â Áõ°Å°¡ ³ô¾ÆÁü¿¡ µû¶ó Áß±¹ ±¹°¡ º¸°Ç À§¿øȸ(National Health Commission)¿¡¼­´Â ÇÁ·Î¹ÙÀÌ¿Àƽ½ºÀÇ »ç¿ëÀ» ±ÇÀåÇÏ°í Àֱ⵵ ÇÏ´Ù [29]. ÇÏÁö¸¸ ¾ÆÁ÷ ¾î¶² Á¾ÀÇ ÇÁ·Î¹ÙÀÌ¿Àƽ½º°¡ COVID-19¿¡ À¯ÀÍÇÏ´Ù´Â °úÇÐÀûÀÎ ¿¬±¸ °á°ú´Â º¸°íµÈ ¹Ù°¡ ¾øÀ¸¸ç, ÇöÀç ¸î¸î ÀÓ»ó ¿¬±¸°¡ ½ÃµµµÇ°í ÀÖÀ¸´Ï ÇÁ·Î¹ÙÀÌ¿Àƽ½ºÀÇ À¯¿ë¼º¿¡ ´ëÇÑ ÆÇ´ÜÀº ÇØ´ç ¿¬±¸ÀÇ °á°ú ÀÌÈÄ·Î ¹Ì·ç¾î µÎ´Â°Ô ÇÕ¸®ÀûÀÏ °ÍÀ¸·Î º¸ÀδÙ.
   ´ëº¯À̽Ä(Fecal microbiota transplantation, FMT) ¹æ¹ýÀ» »ý°¢Çغ¼ ¼öµµ ÀÖ´Ù. Àå³» ȯ°æ ³×Æ®¿öÅ©ÀÇ º¹À⼺À¸·Î ÀÎÇØ ¿ÏÄ¡°¡ ¸Å¿ì ¾î·Æ´Ù°í ¾ð±ÞÇß´ø C. difficile °¨¿°Àº ´ëº¯À̽ÄÀ» ÅëÇØ Àç¹ß·üÀÌ È¹±âÀûÀ¸·Î ¶³¾îÁú ¼ö ÀÖ´Ù´Â °ÍÀÌ È®ÀεǾú´Ù [2]. µû¶ó¼­ Á¦ÇÑÀûÀÌÁö¸¸ ½ÇÁ¦ ÀÓ»ó¿¡¼­ C. difficile °¨¿° Ä¡·á¸¦ À§ÇØ ´ëº¯À̽ÄÀÌ ½Ã¼úµÇ°í ÀÖ´Ù [2]. ÃÖ±Ù C. difficile¿Í SARS-CoV-2¿¡ µ¿½Ã¿¡ °¨¿°µÇ¾ú´ø µÎ¸íÀÇ È¯ÀÚ¸¦ ´ë»óÀ¸·Î ÇÑ ´ëº¯À̽Ŀ¡ ´ëÇÑ ÄÉÀ̽º ·¹Æ÷Æ®¿¡ µû¸£¸é ´ëº¯À̽ÄÀÌ COVID-19ÀÇ È¸º¹À» ºü¸£°Ô ÇÏ´Â È¿°ú¸¦ ³ªÅ¸³Â´Ù [30]. ÀÌ´Â COVID-19 Ä¡·á¿¡ ÀÖ¾î Àå³» ¸¶ÀÌÅ©·Î¹ÙÀÌ¿È ±â¹Ý Ä¡·áÁ¦ÀÇ °³¹ß °¡´É¼ºÀ» °­ÇÏ°Ô ½Ã»çÇÏ´Â º¸°íÀÌ´Ù. ÇÏÁö¸¸ ¿©ÀüÈ÷ ´ëº¯À̽ÄÀÇ È¿°ú¸¦ ´ÜÁ¤Çϱ⿡´Â Á»´õ Å« ±Ô¸ðÀÇ ÀÓ»ó ¿¬±¸ °á°ú°¡ ÇÊ¿äÇϸç, ÇöÀç FeMToCOVID¶ó´Â ¸íĪÀÇ ´ëº¯ÀÌ½Ä ¹æ½ÄÀÇ COVID-19 Ä¡·á ÀÓ»ó µîÀÌ ½ÃµµµÇ°í ÀÖÀ¸´Ï ÇØ´ç °á°ú¸¦ ÁöÄѺ¼ ÇÊ¿ä°¡ ÀÖ´Ù.

[°á·Ð]

  ¸¶ÀÌÅ©·Î¹ÙÀÌ¿ÈÀº 5000¿©Á¾ÀÇ ¹Ì»ý¹° ¼ö½ÊÁ¶°³°¡ ¸ö¾È¿¡ °ÅÁÖÇÏ°í ÀÖ´Ù. À̵éÀº ÁÖ·Î ¼¼±ÕÀÌ ´Ù¼ö¸¦ Â÷ÁöÇϱ⠶§¹®¿¡ ¼¼±ÕÀÇ º¯È­¿¡ ÁÖ¿äÇÑ ¿¬±¸ °á°ú°¡ ÃÊÁ¡À» ¸ÂÃß°í ÀÖÁö¸¸, ¿©±â¼­ ¾ð±ÞÇÑ °õÆÎÀÌ, ¹ÙÀÌ·¯½º »Ó ¾Æ´Ï¶ó ±â»ýÃæ µîÀÇ ´Ù¾çÇÑ ¹Ì»ý¹°µéÀÌ ±¸¼º¿øÀ¸·Î Âü¿©ÇÏ°í ÀÖ´Ù. ¶ÇÇÑ ¼¼±Õ°ú ¼¼±Õ »çÀÌÀÇ »óÈ£ÀÛ¿ë »Ó¸¸ ¾Æ´Ï¶ó ¼¼±Õ°ú ¹ÙÀÌ·¯½º, °õÆÎÀÌ¿Í ¼¼±Õ µî ¹Ì»ý¹° °è °£ ¼­·ÎÀÇ ±¸¼º¿¡ ¿µÇâÀ» ÁÖ°í ¹Þ°í ÀÖÀ¸¸ç, ¼÷ÁÖÀÇ ¸é¿ª ½Ã½ºÅÛ ¿ª½Ã ÀÌ·¯ÇÑ ¹Ì»ý¹°ÀÇ ±¸¼º¿¡ °áÁ¤ÀûÀÎ ¿µÇâÀ» ¹ÌÄ¡°í ÀÖ´Ù. µû¶ó¼­ ¹ÙÀÌ·¯½º¼º °¨¿° ÁúȯÀÎ COVID-19¿¡ À־µµ Àå³» ¸¶ÀÌÅ©·Î¹ÙÀÌ¿È ±¸¼ºÀÌ »ó´çÈ÷ ¿µÇâÀ» ¹Þ´Â °ÍÀº ¸Å¿ì ÀÚ¿¬½º·¯¿ì¸ç ÀÌ·¸°Ô ¿µÇâÀ» ¹ÞÀº Àå³» ¸¶ÀÌÅ©·Î¹ÙÀÌ¿È ±¸¼ºÀº ´Ù½Ã Áúº´ÀÇ ½É°¢µµ¿¡ °áÁ¤ÀûÀÎ ¿ªÇÒÀ» ÇÏ´Â »óÈ£ µÇ¸ÔÀÓ °ü°è¿¡ ³õ¿© ÀÖ´Ù. µû¶ó¼­ ¸î°¡Áö ÇÁ¸®¹ÙÀÌ¿Àƽ½º³ª ÇÁ·Î¹ÙÀÌ¿Àƽ½º·Î µå¶ó¸¶Æ½ÇÑ Ä¡·á È¿°ú¸¦ ±â´ëÇϱ⠾î·Á¿î °ÍÀº ´ç¿¬ÇÒÁöµµ ¸ð¸¥´Ù. ÇÏÁö¸¸ ¸¶ÀÌÅ©·Î¹ÙÀÌ¿È ±â¹ÝÀÇ Ä¡·áÁ¦°¡ ¾Æ´Ï¶ó ÇÏ´õ¶óµµ ¾Õ¼­ ¿©·¯ Áõ°Å¸¦ ÅëÇØ Á¦¾ÈÇÑ ¹Ù¿Í °°ÀÌ COVID-19¸¦ ±Øº¹Çϱâ À§Çؼ­´Â Àå³» ¸¶ÀÌÅ©·Î¹ÙÀÌ¿È°úÀÇ »óÈ£ÀÛ¿ë°ú ±× Á߿伺À» ÀνÄÇÒ ÇÊ¿ä°¡ ÀÖ´Ù. ¶ÇÇÑ ¾ÆÁ÷ °ü·Ã ¿¬±¸°¡ ºÐ¼®¿¡ ±â¹ÝÀ¸·ÎÇÑ »ó°ü°ü°è¸¦ º¸¿©ÁÖ´Â °á°ú°¡ ´ëºÎºÐÀ̶ó COVID-19¿¡¼­ Àå³» ¸¶ÀÌÅ©·Î¹ÙÀÌ¿ÈÀÇ ÀÛ¿ë±âÀüÀ̳ª Á߿伺¿¡ ´ëÇÑ ´õ ¸¹Àº °úÇÐÀû ¿¬±¸ °á°úÀÇ ÃàÀûÀÌ ÇÊ¿äÇÑ ½ÇÁ¤ÀÌ´Ù.

Âü°í¹®Çå

  • 1.

    WHO. https://covid19whoint/ accessed 01-Feb-2022.

  • 2.

    ±èµ¿Çö, ¼­Á¤Èñ. ¸¶ÀÌÅ©·Î¹ÙÀÌ¿È ½Ã´ë - ¶×¶×ÇÑ ¹Ì»ý¹° ³¯¾ÀÇÑ ¹Ì»ý¹°ÀÇ ºñ¹Ð. °³¹Ì. 2019.

  • 3.

    Wang Y, Zhang L, Sang L, et al. Kinetics of viral load and antibody response in relation to COVID-19 severity. J Clin Invest. 2020;130(10):5235-5244.

  • 4.

    Weng J, Li Y, Li J, et al. Gastrointestinal sequelae 90 days after discharge for COVID-19. Lancet Gastroenterol Hepatol. 2021;6(5):344-346

  • 5.

    Han C, Duan C, Zhang S, et al. Digestive Symptoms in COVID-19 Patients With Mild Disease Severity: Clinical Presentation, Stool Viral RNA Testing, and Outcomes. Am J Gastroenterol. 2020;115(6):916-923.

  • 6.

    Buffie CG, Pamer EG. Microbiota-mediated colonization resistance against intestinal pathogens. Nat Rev mmunol. 2013;13(11):790-801.

  • 7.

    Chen Y, Gu S, Chen Y, et al. Six-month follow-up of gut microbiota richness in patients with COVID-19. Gut. 2022;71(1):222-225.

  • 8.

    Tang L, Gu S, Gong Y, et al. Clinical Significance of the Correlation between Changes in the Major Intestinal Bacteria Species and COVID-19 Severity. Engineering (Beijing, China). 2020;6(10):1178-1184.

  • 9.

    Gu S, Chen Y, Wu Z, et al. Alterations of the Gut Microbiota in Patients With Coronavirus Disease 2019 or H1N1 Influenza. Clin Infect Dis. 2020;71(10):2669-2678.

  • 10.

    Yeoh YK, Zuo T, Lui GC, et al. Gut microbiota composition reflects disease severity and dysfunctional immune responses in patients with COVID-19. Gut. 2021;70(4):698-706.

  • 11.

    Zuo T, Zhang F, Lui GCY, et al. Alterations in Gut Microbiota of Patients With COVID-19 During Time of Hospitalization. Gastroenterology. 2020;159(3):944-955.e8.

  • 12.

    Cao J, Wang C, Zhang Y, et al. Integrated gut virome and bacteriome dynamics in COVID-19 patients. Gut microb. 2021;13(1):1-21.

  • 13.

    Sokol H, Contreras V, Maisonnasse P, et al. SARS-CoV-2 infection in nonhuman primates alters the composition and functional activity of the gut microbiota. Gut microb. 2021;13(1):1-19.

  • 14.

    van Tilburg Bernardes E, Pettersen VK, Gutierrez MW, et al. Intestinal fungi are causally implicated in microbiome assembly and immune development in mice. Nat Comm. 2020;11(1):2577.

  • 15.

    Zuo T, Zhan H, Zhang F, et al. Alterations in Fecal Fungal Microbiome of Patients With COVID-19 During Time of Hospitalization until Discharge. Gastroenterology. 2020;159(4):1302-1310.e5.

  • 16.

    Erb Downward JR, Falkowski NR, Mason KL, et al. Modulation of post-antibiotic bacterial community reassembly and host response by Candida albicans. Sci Rep. 2013;3:2191.

  • 17.

    Zuo T, Liu Q, Zhang F, et al. Temporal landscape of human gut RNA and DNA virome in SARS-CoV-2 infection and severity. Microbiome. 2021;9(1):91.

  • 18.

    Virgin HW. The virome in mammalian physiology and disease. Cell. 2014;157(1):142-50.

  • 19.

    Liang G, Bushman FD. The human virome: assembly, composition and host interactions. Nat Rev Microbiol. 2021;19(8):514-527.

  • 20.

    Prasad R, Patton MJ, Floyd JL, et al. Plasma microbiome in COVID-19 subjects: an indicator of gut barrier defects and dysbiosis. bioRxiv 2021:2021.04.06.438634.

  • 21.

    Yoshida N, Emoto T, Yamashita T, et al. Bacteroides vulgatus and Bacteroides dorei Reduce Gut Microbial Lipopolysaccharide Production and Inhibit Atherosclerosis. Circulation. 2018;138(22):2486-2498.

  • 22.

    Baker SA, Kwok S, Berry GJ, et al. Angiotensin-converting enzyme 2 (ACE2) expression increases with age in patients requiring mechanical ventilation. PLoS One. 2021;16(2):e0247060.

  • 23.

    Yu Z, Yang Z, Wang Y, et al. Recent advance of ACE2 and microbiota dysfunction in COVID-19 pathogenesis. Heliyon. 2021;7(7):e07548-e07548.

  • 24.

    Koester ST, Li N, Lachance DM, et al. Variability in digestive and respiratory tract Ace2 expression is associated with the microbiome. PLoS One.2021;16(3):e0248730.

  • 25.

    Zuo T, Liu Q, Zhang F, et al. Depicting SARS-CoV-2 faecal viral activity in association with gut microbiota composition in patients with COVID-19. Gut. 2021;70(2):276-284.

  • 26.

    Gao J, Xu K, Liu H, et al. Impact of the Gut Microbiota on Intestinal Immunity Mediated by Tryptophan Metabolism. Front Cell Infect Microbiol. 2018;8.

  • 27.

    Agus A, Planchais J, Sokol H. Gut Microbiota Regulation of Tryptophan Metabolism in Health and Disease. Cell Host Microbe. 2018;23(6):716-724.

  • 28.

    Lehtoranta L, Pitkaranta A, Korpela R. Probiotics in respiratory virus infections. Eur J Clin Microbiol Infect Dis. 2014;33(8):1289-1302.

  • 29.

    Gao QY, Chen YX, Fang JY. 2019 Novel coronavirus infection and gastrointestinal tract. J Dig Dis. 2020;21(3):125-126.

  • 30.

    Biliski J, Winter K, Jasiński M M, et al. Rapid resolution of COVID-19 after faecal microbiota transplantation. Gut. 2022;71(1):230-232.

ÀúÀÚ¾à·Â

  • 1997-2003

    ¼­¿ï´ëÇб³ ÀÚ¿¬°úÇдëÇÐ ¹Ì»ý¹°ÇÐÀü°ø, ÀÌÇÐ»ç ¹× °ø°ú´ëÇÐ ÄÄÇ»ÅÍ°øÇÐ, °øÇлç

  • 2003-2009

    ¼­¿ï´ëÇб³ ÀÚ¿¬°úÇдëÇÐ »ý¸í°úÇкÎ, ¹Ú»ç

  • 2009-2011

    ¼­¿ï´ëÇб³ ÀÚ¿¬°úÇдëÇÐ, ¼±ÀÓ¿¬±¸¿ø/¿¬¼ö¿¬±¸¿ø

  • 2011-2016

    University of Michigan Medical School, Research fellow

  • 2016-2018

    °¡Å縯´ëÇб³ ÀÇ°ú´ëÇРâÀǽýºÅÛÀÇÇבּ¸¼¾ÅÍ, ¿¬±¸±³¼ö

  • 2018-ÇöÀç

    ¼­¿ï´ëÇб³ ÀÇ°ú´ëÇÐ ÀÇ°úÇаú/¹Ì»ý¹°Çб³½Ç, ºÎ±³¼ö